{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:33:26Z","timestamp":1794605606009,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008730","name":"The Norwegian Cancer Society","doi-asserted-by":"crossref","award":["Contract 194751-2017"],"award-info":[{"award-number":["Contract 194751-2017"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008730","name":"The Norwegian Cancer Society","doi-asserted-by":"crossref","award":["Contract 194751-2017"],"award-info":[{"award-number":["Contract 194751-2017"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008730","name":"The Norwegian Cancer Society","doi-asserted-by":"crossref","award":["Contract 194751-2017"],"award-info":[{"award-number":["Contract 194751-2017"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008730","name":"The Norwegian Cancer Society","doi-asserted-by":"crossref","award":["Contract 194751-2017"],"award-info":[{"award-number":["Contract 194751-2017"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Cancer Society Finland, Sigrid Juselius Foundation, Jane and Aatos Erkko Foundation, Relander Foundation and the Academy of Finland."},{"name":"EJC and DGE are funded by the Manchester National Institute for Health Research (NIHR) Biomedical Research Centre","award":["IS-BRC-1215-20007"],"award-info":[{"award-number":["IS-BRC-1215-20007"]}]},{"name":"EJC and DGE are funded by the Manchester National Institute for Health Research (NIHR) Biomedical Research Centre","award":["IS-BRC-1215-20007"],"award-info":[{"award-number":["IS-BRC-1215-20007"]}]},{"name":"JRS received grant support previously from Health and Care Research Wales for the Wales Gene Park"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The recognition of dominantly inherited micro-satellite instable (MSI) cancers caused by pathogenic variants in one of the four mismatch repair (<jats:italic>MMR<\/jats:italic>) genes <jats:italic>MSH2, MLH1, MSH6<\/jats:italic> and <jats:italic>PMS2<\/jats:italic> has modified our understanding of carcinogenesis. Inherited loss of function variants in each of these <jats:italic>MMR<\/jats:italic> genes cause four dominantly inherited cancer syndromes with different penetrance and expressivities: the four Lynch syndromes. No person has an \u201caverage sex \u201cor a pathogenic variant in an \u201caverage Lynch syndrome gene\u201d and results that are not stratified by gene and sex will be valid for no one. Carcinogenesis may be a linear process from increased cellular division to localized cancer to metastasis. In addition, in the Lynch syndromes (LS) we now recognize a dynamic balance between two stochastic processes: MSI producing abnormal cells, and the host\u2019s adaptive immune system\u2019s ability to remove them. The latter may explain why colonoscopy surveillance does not reduce the incidence of colorectal cancer in LS, while it may improve the prognosis. Most early onset colon, endometrial and ovarian cancers in LS are now cured and most cancer related deaths are after subsequent cancers in other organs. Aspirin reduces the incidence of colorectal and other cancers in LS. Immunotherapy increases the host immune system\u2019s capability to destroy MSI cancers. Colonoscopy surveillance, aspirin prevention and immunotherapy represent major steps forward in personalized precision medicine to prevent and cure inherited MSI cancer.<\/jats:p>","DOI":"10.1186\/s13053-023-00263-3","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T15:02:20Z","timestamp":1697036540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Dominantly inherited micro-satellite instable cancer \u2013 the four Lynch syndromes - an EHTG, PLSD position statement"],"prefix":"10.1186","volume":"21","author":[{"given":"Pal","family":"M\u00f8ller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni T.","family":"Sepp\u00e4l\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysel","family":"Ahadova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma J.","family":"Crosbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Holinski-Feder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Haupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"M\u00f6slein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Winship","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne W. Bajwa-ten","family":"Broeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Kohut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bauerfeind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Gareth","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Aretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf H.","family":"Sijmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Half","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Heinimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Horisberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Monahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia Martina","family":"Cavestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Fruscio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim","family":"Abu-Freha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levi","family":"Zohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Laghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Bertario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Tibiletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo S.","family":"Lino-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Vaccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Della","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedito Mauro","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro Apolin\u00e1rio","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana Lucia","family":"de Oliveira Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma Teresa","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"D\u0119bniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jukka-Pekka","family":"Mecklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Lindblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone","family":"Sunde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigve","family":"Nakken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Heuveline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Burn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eivind","family":"Hovig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kloor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian R.","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mev","family":"Dominguez-Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the Prospective Lynch Syndrome Database (www.plsd.eu) and The European Hereditary Tumour Group (www.ehtg.org)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"263_CR1","doi-asserted-by":"publisher","unstructured":"Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62(6):812\u201323,\u00a0\u00a0https:\/\/doi.org\/10.1136\/gutjnl-2012-304356. https:\/\/pubmed.ncbi.nlm.nih.gov\/23408351\/.","DOI":"10.1136\/gutjnl-2012-304356"},{"key":"263_CR2","unstructured":"InSiGHT variant database, https:\/\/www.insight-group.org\/variants\/databases\/ Accessed dates."},{"key":"263_CR3","doi-asserted-by":"crossref","unstructured":"Boland MJ, Nazor KL, Loring F. Epigenetic regulation of pluripotency and differentiation. Circ Res. 2014; 115: 311\u2013324. https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCRESAHA.115.301517.","DOI":"10.1161\/CIRCRESAHA.115.301517"},{"key":"263_CR4","unstructured":"https:\/\/www.britannica.com\/science\/endoderm Accessed dates."},{"key":"263_CR5","unstructured":"https:\/\/embryology.oit.duke.edu\/GI\/GI.html Accessed dates."},{"key":"263_CR6","doi-asserted-by":"publisher","unstructured":"Tanaka T, Takehara K, Yamashita N, et al. Frequency and clinical features of deficient mismatch repair in ovarian clear cell and endometrioid carcinoma. J Gynecol Oncol. 2022;33(5):e67. https:\/\/doi.org\/10.3802\/jgo.2022.33.e67,\u00a0\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/36032025\/.","DOI":"10.3802\/jgo.2022.33.e67"},{"key":"263_CR7","doi-asserted-by":"publisher","unstructured":"Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1008433. https:\/\/pubmed.ncbi.nlm.nih.gov\/20942669\/.","DOI":"10.1056\/NEJMoa1008433"},{"key":"263_CR8","doi-asserted-by":"publisher","unstructured":"Ligtenberg MJL, Kuiper RP, Geurts van Kessel A. et al. EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients. Familial Cancer. 12: 169\u2013174 (2013). https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.1007\/s10689-012-9591-x.","DOI":"10.1007\/s10689-012-9591-x"},{"key":"263_CR9","doi-asserted-by":"publisher","unstructured":"Vasen HF, M\u00f6slein G, Alonso A, et al. Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Fam Cancer. 2010;9(2):109\u201315. https:\/\/doi.org\/10.1007\/s10689-009-9291-3. https:\/\/pubmed.ncbi.nlm.nih.gov\/19763885\/.","DOI":"10.1007\/s10689-009-9291-3"},{"key":"263_CR10","doi-asserted-by":"publisher","unstructured":"Ahadova A, Sepp\u00e4l\u00e4 TT, Engel C, et al. The \"unnatural\" history of colorectal cancer in Lynch syndrome: Lessons from colonoscopy surveillance. Int J Cancer. 2021 Feb 15;148(4):800-811. doi: https:\/\/doi.org\/10.1002\/ijc.33224. https:\/\/pubmed.ncbi.nlm.nih.gov\/32683684\/.","DOI":"10.1002\/ijc.33224"},{"key":"263_CR11","doi-asserted-by":"publisher","unstructured":"M\u00f8ller P, Sepp\u00e4l\u00e4 T, Bernstein I, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut. 2017;66(3):464\u2013472. https:\/\/doi.org\/10.1136\/gutjnl-2015-309675. https:\/\/pubmed.ncbi.nlm.nih.gov\/26657901\/.","DOI":"10.1136\/gutjnl-2015-309675"},{"key":"263_CR12","doi-asserted-by":"publisher","unstructured":"M\u00f8ller P, Sepp\u00e4l\u00e4 T, Bernstein I, et al. Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. Gut. 2017;66(9):1657\u20131664. https:\/\/doi.org\/10.1136\/gutjnl-2016-311403. https:\/\/pubmed.ncbi.nlm.nih.gov\/27261338\/.","DOI":"10.1136\/gutjnl-2016-311403"},{"key":"263_CR13","doi-asserted-by":"publisher","unstructured":"M\u00f8ller P, Sepp\u00e4l\u00e4 TT, Bernstein I, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut. 2018;67(7):1306\u20131316. https:\/\/doi.org\/10.1136\/gutjnl-2017-314057. https:\/\/pubmed.ncbi.nlm.nih.gov\/28754778\/.","DOI":"10.1136\/gutjnl-2017-314057"},{"key":"263_CR14","doi-asserted-by":"publisher","unstructured":"Dominguez-Valentin M, Haupt S, Sepp\u00e4l\u00e4 TT, et al. Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the Prospective Lynch Syndrome Database. eClinicalMedicine. 2023; 101909, https:\/\/doi.org\/10.1016\/j.eclinm.2023.101909, https:\/\/www.sciencedirect.com\/science\/article\/pii\/S258953702300086X.","DOI":"10.1016\/j.eclinm.2023.101909"},{"key":"263_CR15","doi-asserted-by":"publisher","unstructured":"M\u00f8ller, P., Nakken, S., Hovig, E. Databases: intentions, capabilities, and limitations. In: Valle, L., Gruber, S., Capell\u00e1, G. (eds) Hereditary Colorectal Cancer. Cham: Springer;2018. https:\/\/doi.org\/10.1007\/978-3-319-74259-5_26, https:\/\/doi.org\/10.1007\/978-3-319-74259-5_26.","DOI":"10.1007\/978-3-319-74259-5_26 10.1007\/978-3-319-74259-5_26"},{"key":"263_CR16","doi-asserted-by":"publisher","unstructured":"M\u00f8ller P, Nakken S, Hovig E. The prospective lynch syndrome database. In: Valle L, Gruber S, Capell\u00e1 G. (eds) Hereditary colorectal cancer. Cham: Springer;2018. https:\/\/doi.org\/10.1007\/978-3-319-74259-5_28.","DOI":"10.1007\/978-3-319-74259-5_28"},{"key":"263_CR17","doi-asserted-by":"publisher","unstructured":"M\u00f8ller P. The Prospective lynch syndrome database reports enable evidence-based personal precision health care. Hered Cancer Clin Pract. 2020;18:6. https:\/\/doi.org\/10.1186\/s13053-020-0138-0. https:\/\/pubmed.ncbi.nlm.nih.gov\/32190163\/.","DOI":"10.1186\/s13053-020-0138-0"},{"key":"263_CR18","doi-asserted-by":"publisher","unstructured":"M\u00f8ller, P. The prospective lynch syndrome database: background, design, main results and complete MySQL code. Hered Cancer Clin Pract. 2022. 20: 37 https:\/\/doi.org\/10.1186\/s13053-022-00243-z.","DOI":"10.1186\/s13053-022-00243-z"},{"key":"263_CR19","doi-asserted-by":"publisher","unstructured":"International Mismatch Repair Consortium. Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. Lancet Oncol. 2021;22(7):1014\u20131022. https:\/\/doi.org\/10.1016\/S1470-2045(21)00189-3. https:\/\/pubmed.ncbi.nlm.nih.gov\/34111421\/.","DOI":"10.1016\/S1470-2045(21)00189-3"},{"key":"263_CR20","doi-asserted-by":"publisher","unstructured":"M\u00f8ller P, Sepp\u00e4l\u00e4 T, Dowty JG, et al. Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch repair consortium. Hered Cancer Clin Pract. 2022;20(1):36. https:\/\/doi.org\/10.1186\/s13053-022-00241-1. https:\/\/pubmed.ncbi.nlm.nih.gov\/36182917\/.","DOI":"10.1186\/s13053-022-00241-1"},{"key":"263_CR21","unstructured":"M\u00f8ller P, Dominguez-Valentin M, Sampson JR, et al. Lynch Syndrome, which cancer comes first? https:\/\/www.ehtg.org\/pdf\/EHTG-Meeting-Abstracts-2022.pdf."},{"key":"263_CR22","doi-asserted-by":"publisher","unstructured":"Gallon R, Phelps R, Hayes C, et al. Constitutional mismatch repair deficiency. Gastroenterology. 2022:S0016\u20135085(22)01444\u20135. doi: https:\/\/doi.org\/10.1053\/j.gastro.2022.12.017. https:\/\/pubmed.ncbi.nlm.nih.gov\/36586540\/.","DOI":"10.1053\/j.gastro.2022.12.017"},{"key":"263_CR23","doi-asserted-by":"publisher","unstructured":"Sepp\u00e4l\u00e4 T, Pylv\u00e4n\u00e4inen K, Evans DG, et al. Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a prospective lynch syndrome database report. Hered Cancer Clin Pract. 2017;15:18. https:\/\/doi.org\/10.1186\/s13053-017-0078-5. https:\/\/pubmed.ncbi.nlm.nih.gov\/29046738\/.","DOI":"10.1186\/s13053-017-0078-5"},{"key":"263_CR24","doi-asserted-by":"publisher","unstructured":"Engel C, Vasen HF, Sepp\u00e4l\u00e4 T, et al. No Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance Policies. Gastroenterology. 2018;155(5):1400\u20131409.e2. https:\/\/doi.org\/10.1053\/j.gastro.2018.07.030. https:\/\/pubmed.ncbi.nlm.nih.gov\/30063918\/.","DOI":"10.1053\/j.gastro.2018.07.030"},{"key":"263_CR25","doi-asserted-by":"publisher","unstructured":"Sepp\u00e4l\u00e4 TT, Ahadova A, Dominguez-Valentin M, et al. Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. Hered Cancer Clin Pract. 2019;17:8. https:\/\/doi.org\/10.1186\/s13053-019-0106-8. https:\/\/pubmed.ncbi.nlm.nih.gov\/30858900\/.","DOI":"10.1186\/s13053-019-0106-8"},{"key":"263_CR26","doi-asserted-by":"publisher","unstructured":"Dominguez-Valentin M, Sepp\u00e4l\u00e4 TT, Sampson JR, et al. Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report. Hered Cancer Clin Pract. Hered Cancer Clin Pract. 2019;17:28. https:\/\/doi.org\/10.1186\/s13053-019-0127-3. https:\/\/pubmed.ncbi.nlm.nih.gov\/31636762\/.","DOI":"10.1186\/s13053-019-0127-3"},{"key":"263_CR27","doi-asserted-by":"crossref","unstructured":"Jass JR. Limitations of the Adenoma\u2013Carcinoma Sequence in Colorectum. Clin Cancer Res. 2004; 10 (17): 5969\u20135970. https:\/\/aacrjournals.org\/clincancerres\/article\/10\/17\/5969\/185343\/Limitations-of-the-Adenoma-Carcinoma-Sequence-in.","DOI":"10.1158\/1078-0432.CCR-04-1274"},{"key":"263_CR28","doi-asserted-by":"publisher","unstructured":"Haupt S, Zeilmann A, Ahadova A, et al. Mathematical modeling of multiple pathways in colorectal carcinogenesis using dynamical systems with Kronecker structure. PLoS Comput Biol. 2021;17(5):e1008970. https:\/\/doi.org\/10.1371\/journal.pcbi.1008970. https:\/\/pubmed.ncbi.nlm.nih.gov\/34003820\/.","DOI":"10.1371\/journal.pcbi.1008970"},{"key":"263_CR29","doi-asserted-by":"publisher","unstructured":"Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34(5):424\u20135. https:\/\/doi.org\/10.1007\/BF02053699. https:\/\/pubmed.ncbi.nlm.nih.gov\/2022152\/.","DOI":"10.1007\/BF02053699"},{"key":"263_CR30","doi-asserted-by":"publisher","unstructured":"Vasen FA, Watson P, Mecklin J-P, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC.\u00a0Gastroenterol.\u00a01999;116:1453-1456 https:\/\/doi.org\/10.1016\/S0016-5085(99)70510-X).","DOI":"10.1016\/S0016-5085(99)70510-X"},{"key":"263_CR31","doi-asserted-by":"publisher","unstructured":"Sjursen W, Haukanes BI, Grindedal EM, et al. Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers. J Med Genet. 2010;47(9):579\u201385. https:\/\/doi.org\/10.1136\/jmg.2010.077677. https:\/\/pubmed.ncbi.nlm.nih.gov\/20587412\/.","DOI":"10.1136\/jmg.2010.077677"},{"key":"263_CR32","doi-asserted-by":"publisher","unstructured":"Cavestro GM, Mannucci A, Balaguer F et al. Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) international management guidelines. Clin Gastroenterol Hepatol. 2022:S1542\u20133565(22)01171\u20135. https:\/\/doi.org\/10.1016\/j.cgh.2022.12.006. https:\/\/pubmed.ncbi.nlm.nih.gov\/36549470\/.","DOI":"10.1016\/j.cgh.2022.12.006"},{"key":"263_CR33","doi-asserted-by":"publisher","unstructured":"Peltom\u00e4ki P, Nystr\u00f6m M, Mecklin JP, Sepp\u00e4l\u00e4 TT. Lynch Syndrome Genetics and Clinical Implications. Gastroenterology. 2023:S0016\u20135085(23)00050\u20131. https:\/\/doi.org\/10.1053\/j.gastro.2022.08.058. https:\/\/pubmed.ncbi.nlm.nih.gov\/36706841\/.","DOI":"10.1053\/j.gastro.2022.08.058"},{"key":"263_CR34","unstructured":"https:\/\/hereditarycancer.dfci.harvard.edu\/mylynch\/_w_aa735df3\/assumptions-and-references.pdf Accessed dates."},{"key":"263_CR35","doi-asserted-by":"crossref","unstructured":"Mecklin JP, J\u00e4rvinen HJ, Peltokallio P. Cancer family syndrome. Genetic analysis of 22 Finnish kindreds. Gastroenterology. 1986;90(2):328\u201333. https:\/\/pubmed.ncbi.nlm.nih.gov\/3940911\/.","DOI":"10.1016\/0016-5085(86)90928-5"},{"key":"263_CR36","doi-asserted-by":"publisher","unstructured":"J\u00e4rvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 1995;108(5):1405\u201311. https:\/\/doi.org\/10.1016\/0016-5085(95)90688-6. https:\/\/pubmed.ncbi.nlm.nih.gov\/7729632\/.","DOI":"10.1016\/0016-5085(95)90688-6"},{"key":"263_CR37","doi-asserted-by":"publisher","unstructured":"J\u00e4rvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118(5):829\u201334. https:\/\/doi.org\/10.1016\/s0016-5085(00)70168-5. https:\/\/pubmed.ncbi.nlm.nih.gov\/10784581\/.","DOI":"10.1016\/s0016-5085(00)70168-5"},{"key":"263_CR38","doi-asserted-by":"publisher","unstructured":"Hampel H, Stephens JA, Pukkala E, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology. 2005;129(2):415\u201321. https:\/\/doi.org\/10.1016\/j.gastro.2005.05.011. https:\/\/pubmed.ncbi.nlm.nih.gov\/16083698\/.","DOI":"10.1016\/j.gastro.2005.05.011"},{"key":"263_CR39","doi-asserted-by":"publisher","unstructured":"Bonadona V, Bona\u00efti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305(22):2304\u201310. https:\/\/doi.org\/10.1001\/jama.2011.743. https:\/\/pubmed.ncbi.nlm.nih.gov\/21642682\/.","DOI":"10.1001\/jama.2011.743"},{"key":"263_CR40","doi-asserted-by":"publisher","unstructured":"Finch AP, Lubinski J, M\u00f8ller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547\u201353. https:\/\/doi.org\/10.1200\/JCO.2013.53.2820. https:\/\/pubmed.ncbi.nlm.nih.gov\/24567435\/.","DOI":"10.1200\/JCO.2013.53.2820"},{"key":"263_CR41","doi-asserted-by":"publisher","unstructured":"Dominguez-Valentin M, Crosbie EJ, Engel C, et al. Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. Genet Med. 2021;23(4):705\u2013712. https:\/\/doi.org\/10.1038\/s41436-020-01029-1. https:\/\/pubmed.ncbi.nlm.nih.gov\/33257847\/.","DOI":"10.1038\/s41436-020-01029-1"},{"key":"263_CR42","doi-asserted-by":"publisher","unstructured":"Kloor M, Huth C, Voigt AY, et al. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study. Lancet Oncol. 2012;13(6):598\u2013606. https:\/\/doi.org\/10.1016\/S1470-2045(12)70109-2. https:\/\/pubmed.ncbi.nlm.nih.gov\/22552011\/.","DOI":"10.1016\/S1470-2045(12)70109-2"},{"key":"263_CR43","doi-asserted-by":"publisher","unstructured":"Ahadova A, von Knebel Doeberitz M, Bl\u00e4ker H, Kloor M. CTNNB1-mutant colorectal carcinomas with immediate invasive growth: a model of interval cancers in Lynch syndrome. Fam Cancer. 2016;15(4):579\u201386. https:\/\/doi.org\/10.1007\/s10689-016-9899-z. https:\/\/pubmed.ncbi.nlm.nih.gov\/26960970\/.","DOI":"10.1007\/s10689-016-9899-z"},{"key":"263_CR44","doi-asserted-by":"publisher","unstructured":"Andr\u00e9 T, Cohen R, Salem ME. Immune checkpoint blockade therapy in patients with colorectal cancer harboring microsatellite instability\/mismatch repair deficiency in 2022. Am Soc Clin Oncol Educ Book. 2022;42:1\u20139. https:\/\/doi.org\/10.1200\/EDBK_349557. https:\/\/pubmed.ncbi.nlm.nih.gov\/35471834\/.","DOI":"10.1200\/EDBK_349557"},{"key":"263_CR45","doi-asserted-by":"publisher","unstructured":"Cabez\u00f3n-Guti\u00e9rrez L, Custodio-Cabello S, Palka-Kotlowska M, D\u00edaz-P\u00e9rez D, Mateos-Dominguez M, Galindo-Jara P. Neoadjuvant immunotherapy for dMMR\/MSI-H locally advanced rectal cancer: the future new standard approach? Eur J Surg Oncol. 2022:S0748\u20137983(22)00710\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2022.10.018. https:\/\/pubmed.ncbi.nlm.nih.gov\/36400657\/.","DOI":"10.1016\/j.ejso.2022.10.018"},{"key":"263_CR46","doi-asserted-by":"publisher","unstructured":"Ahadova A, Witt J, Haupt S, et al. Is HLA type a possible cancer risk modifier in Lynch syndrome? Int J Cancer. 2022. https:\/\/doi.org\/10.1002\/ijc.34312. https:\/\/pubmed.ncbi.nlm.nih.gov\/36214792\/.","DOI":"10.1002\/ijc.34312"},{"key":"263_CR47","doi-asserted-by":"publisher","unstructured":"Gebert J, Gelincik O, Oezcan-Wahlbrink M, et al. Recurrent frameshift neoantigen vaccine elicits protective immunity with reduced tumor burden and improved overall survival in a lynch syndrome mouse model. Gastroenterology. 2021;161(4):1288\u20131302.e13. https:\/\/doi.org\/10.1053\/j.gastro.2021.06.073. https:\/\/pubmed.ncbi.nlm.nih.gov\/34224739\/.","DOI":"10.1053\/j.gastro.2021.06.073"},{"key":"263_CR48","doi-asserted-by":"crossref","unstructured":"Kloor M, Reuschenbach M, Pauligk C, et al. Frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers: a phase I\/IIa clinical trial. Clin Cancer Res. 2020;26(17):4503\u20134510. https:\/\/pubmed.ncbi.nlm.nih.gov\/32540851\/.","DOI":"10.1158\/1078-0432.CCR-19-3517"},{"key":"263_CR49","doi-asserted-by":"publisher","unstructured":"Ryser MD, Lange J, Inoue LYT, et al. Estimation of breast cancer overdiagnosis in a U.S. breast screening cohort. Ann Intern Med. 2022;175(4):471\u2013478. https:\/\/doi.org\/10.7326\/M21-3577. https:\/\/pubmed.ncbi.nlm.nih.gov\/35226520\/.","DOI":"10.7326\/M21-3577"},{"key":"263_CR50","doi-asserted-by":"publisher","unstructured":"Dunn BK, Woloshin S, Xie H, Kramer BS. Cancer overdiagnosis: a challenge in the era of screening. J Natl Cancer Cent. 2022;2(4):235\u2013242. https:\/\/doi.org\/10.1016\/j.jncc.2022.08.005. https:\/\/pubmed.ncbi.nlm.nih.gov\/36568283\/.","DOI":"10.1016\/j.jncc.2022.08.005"},{"key":"263_CR51","doi-asserted-by":"publisher","unstructured":"Talseth-Palmer BA, Wijnen JT, Brenne IS, et al . Combined analysis of three Lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriers. Int J Cancer. 2013;132(7):1556\u201364. https:\/\/doi.org\/10.1002\/ijc.27843. https:\/\/pubmed.ncbi.nlm.nih.gov\/22987364\/.","DOI":"10.1002\/ijc.27843"},{"key":"263_CR52","doi-asserted-by":"publisher","unstructured":"Burn J, Sheth H, Elliott F, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet. 2020;395(10240):1855\u20131863. https:\/\/doi.org\/10.1016\/S0140-6736(20)30366-4. https:\/\/pubmed.ncbi.nlm.nih.gov\/32534647\/.","DOI":"10.1016\/S0140-6736(20)30366-4"},{"key":"263_CR53","doi-asserted-by":"publisher","unstructured":"Zumwalt TJ, Wodarz D, Komarova NL, et al. Aspirin-induced chemoprevention and response kinetics are enhanced by PIK3CA mutations in colorectal cancer cells. Cancer Prev Res (Phila). 2017;10(3):208\u2013218. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-16-0175. https:\/\/pubmed.ncbi.nlm.nih.gov\/28154202\/.","DOI":"10.1158\/1940-6207.CAPR-16-0175"},{"key":"263_CR54","doi-asserted-by":"publisher","unstructured":"Mathers JC, Elliott F, Macrae F, et al. Cancer prevention with resistant starch in Lynch Syndrome Patients in the CAPP2-Randomized placebo controlled trial: planned 10-Year follow-up. Cancer Prev Res (Phila). 2022;15(9):623\u2013634. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-22-0044. https:\/\/pubmed.ncbi.nlm.nih.gov\/35878732\/.","DOI":"10.1158\/1940-6207.CAPR-22-0044"},{"key":"263_CR55","unstructured":"https:\/\/rarediseases.info.nih.gov\/diseases\/6821\/muir-torre-syndrome Accessed dates."},{"key":"263_CR56","doi-asserted-by":"publisher","unstructured":"Ahadova A, Gallon R, Gebert J, et al. Three molecular pathways model colorectal carcinogenesis in Lynch syndrome. Int J Cancer. 2018;143(1):139\u2013150. https:\/\/doi.org\/10.1002\/ijc.31300,\u00a0 \u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/29424427\/.","DOI":"10.1002\/ijc.31300"},{"key":"263_CR57","doi-asserted-by":"publisher","unstructured":"Malesci A, Laghi L, Bianchi P, et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res. 2007;13(13):3831\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0366. https:\/\/pubmed.ncbi.nlm.nih.gov\/17606714\/.","DOI":"10.1158\/1078-0432.CCR-07-0366"},{"key":"263_CR58","unstructured":"M\u00f8ller P, Haupt S, Ahadova A, et al An additional carcinogenetic mechanism for colon cancer in Lynch syndrome https:\/\/www.ehtg.org\/pdf\/EHTG-Meeting-Abstracts-2022.pdf."},{"issue":"7","key":"263_CR59","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/ejhg.2015.252","volume":"24","author":"AM Jansen","year":"2016","unstructured":"Jansen AM, van Wezel T, van den Akker BE, et al. Combined mismatch repair and POLE\/POLD1 defects explain unresolved suspected Lynch syndrome cancers. Eur J Hum Genet. 2016;24(7):1089\u201392. https:\/\/doi.org\/10.1038\/ejhg.2015.252.","journal-title":"Eur J Hum Genet."},{"key":"263_CR60","doi-asserted-by":"publisher","unstructured":"Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26(22):3785\u201390. https:\/\/doi.org\/10.1200\/JCO.2008.16.0812. https:\/\/pubmed.ncbi.nlm.nih.gov\/18591545\/.","DOI":"10.1200\/JCO.2008.16.0812"},{"key":"263_CR61","doi-asserted-by":"crossref","unstructured":"Gupta R, Sinha S, Paul RN. The impact of microsatellite stability status in colorectal cancer. Curr Prob Cancer. 2018; 42(6):548\u2013559, https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0147027217301691?via%3Dihub.","DOI":"10.1016\/j.currproblcancer.2018.06.010"}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-023-00263-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13053-023-00263-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-023-00263-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T07:36:21Z","timestamp":1700552181000},"score":1,"resource":{"primary":{"URL":"https:\/\/hccpjournal.biomedcentral.com\/articles\/10.1186\/s13053-023-00263-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["263"],"URL":"https:\/\/doi.org\/10.1186\/s13053-023-00263-3","relation":{},"ISSN":["1897-4287"],"issn-type":[{"value":"1897-4287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,11]]},"assertion":[{"value":"13 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Toni T. Sepp\u00e4l\u00e4: Healthfund Finland (CEO and stock holding), LS Cancer Diag (advisory board and stock holding) and Amgen Finland (speaker honorarium).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}